Abstract: The present technology relates to circuitry immunity to electrical interference, such as Electrical Fast Transient (EFT) interference. In an example embodiment, an interference dissipation circuit is provided. The interference dissipation circuit includes a transient voltage suppression (TVS) sub-circuit, a ferrite bead having a first terminal and a second terminal, a capacitor coupled in series with the ferrite bead and having a first terminal and a second terminal. The TVS sub-circuit includes a plurality of TVS ports, and the TVS sub-circuit is coupled to the set of output ports at a first set of TVS ports of the plurality of TVS ports. The ferrite bead is coupled to a ground port of the plurality of TVS ports, the second terminal of the ferrite bead is coupled to the first terminal of the capacitor, and the second terminal of the capacitor is coupled to a chassis in an industrial automation environment.

Abstract: A system for identifying movers in an independent cart system includes movers having at least one magnet and sensors generating a feedback signal responsive to detecting a magnetic field from the magnet as each mover travels past the sensor. A memory stores an identifier and a corresponding digital fingerprint for each mover. The stored digital fingerprint is generated as a function of the magnetic field generated by the magnet on each mover. A controller receives the feedback signal from each sensor and determines a run-time digital fingerprint for each mover corresponding to the magnetic field generated by the magnet on each mover as a function of the feedback signal. The run-time digital fingerprint is matched to one of the stored digital fingerprints, and the identifier, corresponding to the stored digital fingerprint matching the run-time fingerprint, is read from memory.

Abstract: The present disclosure provides multispecific binding molecules that specifically bind to BCMA, a component of a human T-cell receptor complex and either CD2 or a tumor associated antigen, conjugates comprising the multispecific binding molecules, and pharmaceutical compositions comprising the multispecific binding molecules and the conjugates. The disclosure further provides methods of using the multispecific binding molecules to treat disease and disorders associated with expression of BCMA. The disclosure yet further provides recombinant host cells engineered to express the multispecific binding molecules and methods of producing the multispecific binding molecules by culturing the host cells under conditions in which the multispecific binding molecules are expressed.

Abstract: A system for identifying movers in an independent cart system includes movers having at least one magnet and sensors generating a feedback signal responsive to detecting a magnetic field from the magnet as each mover travels past the sensor. A memory stores an identifier and a corresponding digital fingerprint for each mover. The stored digital fingerprint is generated as a function of the magnetic field generated by the magnet on each mover. A controller receives the feedback signal from each sensor and determines a run-time digital fingerprint for each mover corresponding to the magnetic field generated by the magnet on each mover as a function of the feedback signal. The run-time digital fingerprint is matched to one of the stored digital fingerprints, and the identifier, corresponding to the stored digital fingerprint matching the run-time fingerprint, is read from memory.

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting agent which is an anti-BCMA antibody molecule or a recombinant non-antibody protein that binds to BCMA, and a gamma secretase inhibitor.

Abstract: The present disclosure relates to dosage regimes of anti-CD19 agents, in particular an anti-CD19×anti-CD3×anti-CD2 trispecific agent administered intravenously (i.v.) and subcutaneously (s.c.), and their use for treating diseases and disorders associated with expression of CD19 such as B cell malignancies, in particular relapsed and/or refractory B-cell malignancies.

Abstract: A common-mode interference dissipation circuit to provide circuitry immunity to electrical interference, such as common mode impedance interference, is described herein. The common-mode interference dissipation circuit may include one or more variable resistors each having a first terminal and a second terminal and a capacitor coupled in series with the one or more variable resistors and having a first terminal and a second terminal. The first terminal of the one or more variable resistors may be coupled to a port of the first set of ports, the second terminal of the one or more variable resistors may be coupled to the first terminal of the capacitor, and the second terminal of the capacitor may be coupled to a chassis in an industrial automation environment.

Abstract: An independent cart system includes multiple track segments, multiple movers, multiple position sensors, and a controller. Each track segment includes multiple coils along a length of the track segment and a segment controller operative to selectively energize the coils to generate an electromagnetic field. Each mover includes a magnet array having multiple magnets, where the magnet array generates a magnetic field that interacts with the electromagnetic field generated by the coils to propel the mover along the track segments. The position sensors are spaced apart along the length of each track segment and generate a position feedback signal with a waveform as a function of the magnetic field generated by the magnet array on each mover. The controller is operative to receive the position feedback signal from each position sensor and to determine a unique identifier for each mover as a function of the waveform of the position feedback signal.

Abstract: A common-mode interference dissipation circuit to provide circuitry immunity to electrical interference, such as common mode impedance interference, is described herein. The common-mode interference dissipation circuit may include one or more variable resistors each having a first terminal and a second terminal and a capacitor coupled in series with the one or more variable resistors and having a first terminal and a second terminal. The first terminal of the one or more variable resistors may be coupled to a port of the first set of ports, the second terminal of the one or more variable resistors may be coupled to the first terminal of the capacitor, and the second terminal of the capacitor may be coupled to a chassis in an industrial automation environment.

Abstract: The present technology relates to circuitry immunity to electrical interference, such as Electrical Fast Transient (EFT) interference. In an example embodiment, an interference dissipation circuit is provided. The interference dissipation circuit includes a transient voltage suppression (TVS) sub-circuit, a ferrite bead having a first terminal and a second terminal, a capacitor coupled in series with the ferrite bead and having a first terminal and a second terminal. The TVS sub-circuit includes a plurality of TVS ports, and the TVS sub-circuit is coupled to the set of output ports at a first set of TVS ports of the plurality of TVS ports. The ferrite bead is coupled to a ground port of the plurality of TVS ports, the second terminal of the ferrite bead is coupled to the first terminal of the capacitor, and the second terminal of the capacitor is coupled to a chassis in an industrial automation environment.

Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19 including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.

Abstract: The present disclosure provides combinations of anti-CD19 agents and B cell targeting agents and methods of treating subjects having B cell malignancies with combinations of anti-CD19 agents and a B cell targeting agents.

Abstract: An independent cart system includes multiple track segments, multiple movers, multiple position sensors, and a controller. Each track segment includes multiple coils along a length of the track segment and a segment controller operative to selectively energize the coils to generate an electromagnetic field. Each mover includes a magnet array having multiple magnets, where the magnet array generates a magnetic field that interacts with the electromagnetic field generated by the coils to propel the mover along the track segments. The position sensors are spaced apart along the length of each track segment and generate a position feedback signal with a waveform as a function of the magnetic field generated by the magnet array on each mover. The controller is operative to receive the position feedback signal from each position sensor and to determine a unique identifier for each mover as a function of the waveform of the position feedback signal.

Abstract: A system for identifying movers in an independent cart system includes movers having at least one magnet and sensors generating a feedback signal responsive to detecting a magnetic field from the magnet as each mover travels past the sensor. A memory stores an identifier and a corresponding digital fingerprint for each mover. The stored digital fingerprint is generated as a function of the magnetic field generated by the magnet on each mover. A controller receives the feedback signal from each sensor and determines a run-time digital fingerprint for each mover corresponding to the magnetic field generated by the magnet on each mover as a function of the feedback signal. The run-time digital fingerprint is matched to one of the stored digital fingerprints, and the identifier, corresponding to the stored digital fingerprint matching the run-time fingerprint, is read from memory.

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.

Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

Abstract: The present disclosure provides multispecific binding molecules that specifically bind to BCMA, a component of a human T-cell receptor complex and either CD2 or a tumor associated antigen, conjugates comprising the multispecific binding molecules, and pharmaceutical compositions comprising the multispecific binding molecules and the conjugates The disclosure further provides methods of using the multispecific binding molecules to treat disease and disorders associated with expression of BCMA. The disclosure yet further provides recombinant host cells engineered to express the multispecific binding molecules and methods of producing the multispecific binding molecules by culturing the host cells under conditions in which the multispecific binding molecules are expressed.